30 closest matches · ranked by relevance
Acute Bleeding on Long-Term Anticoagulation Therapy · Hemorrhage · Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time)
Primary: Number of Participants Who Demonstrated Significant Reversal of INR Within 15 Minutes — 21; 33 Participants
Significant Bleeding Risk
Primary: Hemostatic Efficacy Rating by IEAB — 41; 50; 58; 47 Participants
Hemorrhage
Primary: Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of dTT or ECT — 100.0; 100.0; 100.0; 100.0 percentage
Reversal of Anticoagulant Treatment
Primary: INR Response — 74; 31 Participants
COVID-19
Primary: Composite Outcome of ICU Admission, Non-invasive Positive Pressure Ventilation, Invasive Mechanical Ventilation, or All-cause Death up to 28 Days. — 37; 52 Participants
Hemorrhage
Primary: Number of Participants With Drug-related Adverse Events (AEs) — 0 Participants
Bleeding · Hemorrhage
Primary: INTEM HEPTEM and FIBTEM Test of the ROTEM Coagulation Analyzer — 98; 117; 178; 253 seconds
Healthy
Primary: Subjects Achieving Complete Reversal of Anticoagulation (WBCT is ≤ 110% of Baseline) — 3; 7; 11; 11 Participants
Acute Coagulopathy
Primary: 28 Day In-hospital Mortality — 20; 11 participants — p=0.04
Atrial Fibrillation · Catheter Ablation
Primary: Time to Ambulation — 480; 316 minutes — p=<0.001
Reversal of Coagulopathy
Primary: Percentage of Participants Achieving Hemostatic Efficacy During Surgery — 89.7; 75.3 percentage of participants
Atrial Fibrillation
Primary: The Number of Patients With Emergency Surgery and Major Bleeding Due to Fracture or Trauma. — 14; 35; 84 Number of Patients
Blood Coagulation Disorders · Acute Major Bleeding
Primary: Percentage of Participants Achieving Hemostatic Efficacy of Stopping an Ongoing Major Bleed — 72.4; 65.4 percentage of participants
Hypofibrinogenemia · Bleeding
Primary: Total Number of RBCs Used Over Admission — 5.8; 6.7 RBC Units
Cirrhosis · Coagulopathy
Primary: Intra-operative Blood Loss — 2000; 3000 milliliters
Focus of Study · Coagulation Status of Cardiac Surgery Patient · Reducing Excess Blood Transfusion
Primary: Change in Thromboelastography-derived Functional Fibrinogen Level (FLEV) — -1.1 mg/dL
Bleeding · Blood Loss, Surgical · Cardiovascular Surgical Procedures
Primary: Chest Tube Output — 1022; 937 mL — p=0.84
Healthy
Primary: Subjects Achieving Complete Reversal of Anticoagulation (WBCT is ≤ 110% of Baseline) — 2; 9; 12; 12 Participants
Acute ST Segment Elevation Myocardial Infarction
Primary: Platelet Inhibition Measured With Optical Aggregometry — 109; 253.8 AU*min
Bleeding Disorder · Hypofibrinogenemia; Acquired
Primary: Intra-operative Blood Loss — 1380.7; 1660.13 mL — p=<0.001
Hemorrhage
Primary: Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Ecarin Clotting Time — 100.0; 100.0; 100.0 Percentage
Congenital Heart Disease
Primary: Total Units of Intraoperative Allogenic Donor Transfusions (ADT) Administered During Procedure Through ICU Arrival. — 5; 4 ADT units
Obstetric Labor Complications · Hemorrhage · Complications; Cesarean Section
Primary: Fibrinogen Level at 2 Hours After Delivery — 186; 418 mg/dL — p=<0.05
Hemorrhage
Primary: Reversal of Dabigatran-induced Prolongation of Blood Coagulation Time — 0.0; 100.0; 0.0; 100.0 percentage of participants
Trauma Injury
Primary: Number of Participants With Mortality From Any Cause — 201; 192 Participants
Liver Fibrosis
Primary: Median Liver Stiffness Value — 7.70; 6.90 kPa — p=0.043
Acute Hypoxemic Respiratory Failure · Anticoagulant-induced Bleeding · Thromboembolism
Primary: Number of Participants With Major Bleeding Events — 1; 4 Participants
Spinal Fusion · Cardiopulmonary Bypass
Primary: International Normalized Ratio (INR) on CoaguChek — 1.11; 4.6 ratio
Hemorrhage
Primary: Percentage of Subjects With Drug-related Adverse Events — 0.0 Percentage of participants
COVID 19 Associated Coagulopathy
Primary: Mortality — 18; 13 Participants